Exact Sciences (EXAS) said Tuesday results from a new 20-year study validated adverse pathology as a predictor of prostate cancer outcomes in clinically...
Exact Sciences (EXAS) said Thursday it partnered with Philadelphia-based primary-care provider Jefferson Health for research on a new blood-based,...
Kevin T Conroy, Director, President and CEO, on November 01, 2021, sold 16,922 shares in Exact Sciences (EXAS) for $1,588,637. Following the Form 4 filing...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
| Address | 5505 Endeavor Lane Madison, Wisconsin 53719 |
| Phone | +1.608.284.5700 |
| Number of Employees | 1,977 |
| Recent SEC Filing | 11/05/2021 3 |
| Chairman, President & Chief Executive Officer | Kevin T. Conroy |
| Senior Vice President-Operations | Ana Hooker |
| Executive VP, Chief Operating & Financial Officer | Jeffrey Thomas Elliott |
| Chief Science Officer, SVP-Research & Development | Graham Peter Lidgard |
| Price Open | $89.16 |
| Previous Close | $88.09 |
| 52 Week Range | $81.07 - 159.54 |
| Market Capitalization | $14.7 B |
| Shares Outstanding | 172.3 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 02/15/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$2.80 |
| Beta vs. S&P 500 | N/A |
| Revenue | $454.5 M |
| Net Profit Margin | -46.14% |
| Return on Equity | -24.07% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
